Safety Profile and Outcomes of Early COVID-19 Treatments in Immunocompromised Patients: A Single-Centre Cohort Study

Background: Early treatment with remdesivir (RMD) or monoclonal antibodies (mAbs) could be a valuable tool in patients at risk of severe COVID-19 with unsatisfactory responses to vaccination. We aim to assess the safety and clinical outcomes of these treatments among immunocompromised subjects. Meth...

Descripción completa

Detalles Bibliográficos
Autores principales: Biscarini, Simona, Villa, Simone, Genovese, Camilla, Tomasello, Mara, Tonizzo, Anna, Fava, Marco, Iannotti, Nathalie, Bolis, Matteo, Mariani, Bianca, Valzano, Antonia Grazia, Morlacchi, Letizia Corinna, Donato, Francesca, Castellano, Giuseppe, Cassin, Ramona, Carrabba, Maria, Muscatello, Antonio, Gori, Andrea, Bandera, Alessandra, Lombardi, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405567/
https://www.ncbi.nlm.nih.gov/pubmed/36009549
http://dx.doi.org/10.3390/biomedicines10082002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405567/
https://www.ncbi.nlm.nih.gov/pubmed/36009549
http://dx.doi.org/10.3390/biomedicines10082002

Ejemplares similares